Insights
OHE’s contribution to health economics
1 May 2023
‘Health economists often credit the UK with being the natural home for the discipline – why?’ We conducted interviews with 18 esteemed health economists to explore…
How Restrictive are NICE ‘Optimised’ Decisions?
27 April 2023
NICE makes ‘optimised’ decisions to support use of medicines in smaller groups of patients. Between 2020 to 2022, 56% of optimised decisions recommended treatment for less than half of eligible patients.
Around The World in HTAs: Italy – What’s Next?
20 April 2023
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Claudio Jommi, Università del Piemonte Orientale Novara, and Martina Garau, OHE, take us to Italy.
Caring about Carers: Improving Consideration of the Burden of Informal Caring in HTA
11 April 2023
Through a three-part webinar series, commissioned and funded by Roche, OHE has explored the burdens on informal carers when providing unpaid care for loved ones.
Around The World in HTAs: Spain – Are We There Yet?
15 March 2023
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Laura Vallejo-Torres, University of Las Palmas de Gran Canaria, and Patricia Cubi-Molla, OHE, take us to Spain.
Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?
15 February 2023
Gene therapies pose fresh challenges for discounting practice by HTA agencies. In this blog, we discuss why discounting is important for gene therapies, using a potential gene therapy for X-Linked Retinitis Pigmentosa (XLRP) as an example.
Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges
6 February 2023
During an engaging discussion of Professor Aidan Hollis’ prizewinning proposal with Professor Adrian Towse a range of potential benefits and remaining questions were explored.
Combination Therapies: A Step Forward to the Value Attribution Problem
4 January 2023
OHE convened a roundtable discussion to present and discuss recent work by OHE colleagues and collaborators on value attribution frameworks for combination therapies.
G7 Investments in New Antibiotics Would Pay Off – For Everyone
9 December 2022
Programs to incentivise antibiotic R&D are underway in the UK and under consideration in the US, EU, Canada, and Japan. We have assessed the benefits and costs to the members of the G7/EU and project that all G7/EU members would see big payoffs ranging from 11:1 in the UK to 28:1 for the US and Japan. Global returns from reducing the 1.27m people dying each year from AMR are even higher.